Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2023
Qizheng Tibetan Medicine, Chairwoman Lei Jufang Warned Over Undisclosed RMB151M Related-Party CD Deals With Controlling Shareholder
From August 2022 to March 2023, Qizheng Tibetan Medicine and controlling shareholder Gansu Qizheng Industrial cumulatively traded transferable large-denomination certificates of deposit worth RMB151 million, without going through review procedures and without disclosing them in periodic reports. The Tibet Securities Regulatory Bureau issued warning letters to the company and Chairwoman Lei Jufang, General Manager Liu Kailie, CFO Yao Xiaomei, and Board Secretary Feng Ping; in December, the Shenzhen Stock Exchange issued a regulatory letter based on cumulative related-party transactions of RMB181 million. Status: regulatory measures. Entities involved: Tibet Qizheng Tibetan Medicine Co., Ltd., Gansu Qizheng Industrial Group Co., Ltd., Lei Jufang. Scope: related-party transactions.